161 related articles for article (PubMed ID: 18430123)
1. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.
Jensen HK; Nordsmark M; Donskov F; Marcussen N; von der Maase H
BJU Int; 2008 Jun; 101 Suppl 4():41-4. PubMed ID: 18430123
[No Abstract] [Full Text] [Related]
2. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.
Shuch B; Li Z; Belldegrun AS
BJU Int; 2008 Jun; 101 Suppl 4():25-30. PubMed ID: 18430119
[No Abstract] [Full Text] [Related]
3. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
Signoretti S; Regan M; Atkins M
BJU Int; 2008 Jun; 101 Suppl 4():31-5. PubMed ID: 18430120
[No Abstract] [Full Text] [Related]
4. Carbonic anhydrase IX: historical and future perspectives.
Oosterwijk E
BJU Int; 2008 Jun; 101 Suppl 4():2-7. PubMed ID: 18430115
[No Abstract] [Full Text] [Related]
5. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
Leppert JT; Lam JS; Pantuck AJ; Figlin RA; Belldegrun AS
BJU Int; 2005 Aug; 96(3):281-5. PubMed ID: 16042714
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
7. Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma.
Pantuck AJ; Klatte T; Seligson D; Atkins M; Belldegrun A
J Clin Oncol; 2008 Jun; 26(18):3105-7; author reply 3107-9. PubMed ID: 18565906
[No Abstract] [Full Text] [Related]
8. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma.
Dudek AZ; Yee RT; Manivel JC; Isaksson R; Yee HO
Anticancer Res; 2010 Mar; 30(3):987-92. PubMed ID: 20393025
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia.
Pastorekova S; Ratcliffe PJ; Pastorek J
BJU Int; 2008 Jun; 101 Suppl 4():8-15. PubMed ID: 18430116
[No Abstract] [Full Text] [Related]
11. [Comment to "Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression"].
Salinas AS
Actas Urol Esp; 2011 Feb; 35(2):87-8. PubMed ID: 21288602
[No Abstract] [Full Text] [Related]
12. Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis.
Giménez-Bachs JM; Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SH; Rubio-Del Campo A; Sánchez-Prieto R
Scand J Urol Nephrol; 2012 Oct; 46(5):358-64. PubMed ID: 22571179
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Lamers CH; Sleijfer S; Vulto AG; Kruit WH; Kliffen M; Debets R; Gratama JW; Stoter G; Oosterwijk E
J Clin Oncol; 2006 May; 24(13):e20-2. PubMed ID: 16648493
[No Abstract] [Full Text] [Related]
14. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
[TBL] [Abstract][Full Text] [Related]
15. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
Brouwers AH; Mulders PF; Oyen WJ
J Clin Oncol; 2008 Aug; 26(22):3808-9; author reply 3811-2. PubMed ID: 18669472
[No Abstract] [Full Text] [Related]
16. In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer.
Brouwers AH; Boerman OC; Oyen WJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8886; author reply 8886. PubMed ID: 16361579
[No Abstract] [Full Text] [Related]
17. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
Panelli MC; Wang E; Marincola FM
Clin Cancer Res; 2005 May; 11(10):3601-3. PubMed ID: 15897553
[No Abstract] [Full Text] [Related]
18. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer.
Li G; Feng G; Gentil-Perret A; Genin C; Tostain J
J Urol; 2008 Aug; 180(2):510-3; discussion 513-4. PubMed ID: 18550116
[TBL] [Abstract][Full Text] [Related]
19. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
[TBL] [Abstract][Full Text] [Related]
20. The use of positron-emission tomography in the diagnosis of tumour phenotype.
Divgi C
BJU Int; 2008 Jun; 101 Suppl 4():36-8. PubMed ID: 18430121
[No Abstract] [Full Text] [Related]
[Next] [New Search]
